Trial Profile
A phase II study of Gleevec (imatinib mesylate formerly known as STI571) in chemotherapy refractory germ cell tumors expressing Kit
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Jan 2006
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Germ cell and embryonal neoplasms; Germ cell cancer
- Focus Therapeutic Use
- 26 Jan 2006 New trial record.